Microsoft word - optinose - crs rhinology journal release final - 10 19 10
New Data Show Therapeutic Benefits in Chronic Rhinosinusitis Patients Using Fluticasone Delivered by OptiNose’s Novel Delivery Technology -OptiNose announces publication of positive clinical results highlighting Company’s bi-directional drug -Results further demonstrate efficacy potential of OptiNose technology across multiple conditions- Yardley, PA – October 20, 2010 – Today OptiNose Inc. announced the positive results of a study evaluating the efficacy of fluticasone when delivered by the Company’s novel bi-directional technology in patients with refractory chronic rhinosinusitis (CRS). The results of the study have been published in an article in the September issue of Rhinology. The paper, entitled “Preliminary efficacy of fluticasone delivered by a novel device in recalcitrant chronic rhinosinusitis,” is authored by rhinologists Fleur S. Hansen, M.D, Per G. Djupesland, M.D., Ph.D., Chief Scientific Officer (CSO) of OptiNose and inventor of the Company’s bi-directional delivery technology, and the principle investigator, Professor Wytske J. Fokkens, M.D., Ph.D., Chair of ENT Department at the Academic Medical Centre, Amsterdam, The Netherlands. The results show administering fluticasone with OptiNose’s device is effective in the treatment of refractory CRS, with significant and clinically relevant improvements compared with placebo in both subjective and objective measures of the disease. Chronic rhinosinusitis affects approximately 12 percent of Americans below the age of 45, causing both physical symptoms and reduced quality of life. In Europe, between 7 and 27 percent of the urban population has been reported to have CRS. While current medical therapies including oral steroids, antibiotics and intranasal steroids may reduce inflammation and relieve symptoms, many patients and healthcare providers remain unsatisfied with these options. Frustratingly, many recent trials with novel topical and systemic treatment modalities have failed, leaving a substantial opportunity for improved treatments. Professor Fokkens commented, “Chronic rhinosinusitis can be very debilitating and these results are encouraging for patients suffering from this disease. There is a significant unmet medical need in CRS given the limitations of current treatment options. This study demonstrates the importance of how treatment delivery can be a key determinant of treatment success. OptiNose’s bi-directional technology showed remarkably good results in patients with chronic rhinosinusitis who did not sufficiently respond to standard medical treatment and repeated surgery.” Highlights of the prospective, randomized, double-blind, placebo-controlled, parallel study of 20 adult patients with longstanding refractory CRS to medical and surgical treatment include: Objective Results:
Endoscopy score for inflammatory mucosal swelling in the key region for sinus ventilation,
showed a significant and progressive improvement and normalization after 12 weeks treatment of the severely swollen mucosa.
After 12 weeks, there were significant improvements in the MRI scores in the OptiNose group as
compared to baseline and a positive trend as compared to placebo.
The nasal domain of the quality of life assessment (RSOM-31) was significantly improved with
OptiNose treatment as compared with placebo.
Nasal discomfort and combined scores were significantly improved during morning and evening
Sense of smell was improved with statistically significant scores versus placebo after 12 weeks.
Per G. Djupesland commented, “The results of this study provide preliminary evidence suggesting fluticasone coupled with OptiNose’s technology is an effective and well-tolerated treatment for patients with chronic rhinosinusitis. The key to OptiNose’s success is its ability to transport an effective anti-inflammatory medication to targeted areas beyond the nasal valve, including the middle meatus, which is
key for normal sinus ventilation, normal function of the nose and the sense of smell. These findings corroborate the results of previous studies on patients with CRS and provide further evidence suggesting that the OptiNose drug delivery technology may have a significant impact on patients across multiple medical conditions.” About OptiNose Inc. OptiNose is a drug delivery company with breakthrough bi-directional nasal technology set to transform the static nasal drug delivery market. Founded in 2000, OptiNose’s devices are designed to deliver intranasal drugs to target regions of the nasal cavity, including the sinuses and the olfactory region while preventing lung deposition. The company offers both single and multi-use intranasal delivery devices for liquid and powder formulations. The technology has been successfully tested in a number of clinical trials with results confirming the superiority of the technology compared to traditional nasal sprays. Investors in OptiNose include Avista Capital Partners in New York, WFD Ventures LLC located in New York and Entrepreneurs Fund LP based in Jersey, Channel Islands. For more information please visit www.OptiNose.com. About Bi-directional Nasal Delivery Technology OptiNose’s bidirectional nasal delivery technology significantly improves delivery to the targeted sites deep into the nose where the openings to the sinuses are located, which is considered essential to achieving clinical effects in CRS with topical treatments. While exhaling into the device, the soft palate automatically closes off the nasal cavity completely. The breath enters one nostril through a sealing nozzle and triggers the release of drug particles into the airflow. This action causes the narrow nasal passages to expand and carry these particles beyond the nasal valve to targeted sites. After delivering drug particles to the targeted sites, the air flow then exits the nasal cavity through the other nasal passage in the opposite direction.
SISC Flex Plan HEALTH CARE AND DEPENDENT CARE EXPENSES *Please note, all "potentially eligible expenses" require a Certification of Medical Necessity form completed by your medical practitioner in order to be considered eligible for reimbursement. The letter must include 1. Medical condition/diagnosis 2. Specific recommended treatment 3. Duration of treatment. This letter must be sub
PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2014 The 2014 Prohibited List 11 September 2013 THE 2014 PROHIBITED LIST